Breathing is the only vital sign that is both automatic and voluntarily controllable, and it is the one modern wearables measure worst. Heart rate, oxygen, and temperature are tracked continuously, yet respiration is still inferred indirectly from wrist motion or heart-rate proxies, or captured only during clinical spot-checks. Alveos One makes breathing a true, continuous vital sign that can be measured and acted on in everyday life.

Alveos One is a lightweight, clothing-worn device built on a mechano-acoustic sensing method. Rather than using cameras, optical PPG, or airflow masks, it detects the subtle chest vibrations and pressure changes produced directly by airflow and chest-wall motion during respiration. A high-sensitivity acoustic sensor rests against the skin via a magnetic clip that maintains stable contact without adhesives or skin preparation (Fig. 1, enclosure; Fig. 2, internal components). Raw acoustic signals are processed on-device to characterize breathing rate, rhythm, and depth, and machine-learning models—trained on respiratory data across body types, activity levels, and noise conditions—interpret breathing dynamics over time.

What makes the design novel is the combination of a direct mechano-acoustic signature with real-time, in-the-moment guidance. Most wearables explain a state shift after it happens; Alveos One detects the shift as it begins - rising stress, stalled recovery, drifting sleep, dropping focus - and triggers a haptic nudge as well as an adaptive 1–30 minute breathing protocol through an on-device AI Breath Coach, with haptic feedback that works even without a phone (Fig. 3, app and coaching flow). Because breathing reflects physical exertion, stress, recovery, and autonomic nervous-system activity, this turns a passive metric into a closed-loop intervention.

Feasibility is high. The device uses compact, off-the-shelf acoustic sensing components and a simple magnetic mechanical design, processes data locally to minimize cost and protect privacy, runs up to eight days per charge, and recharges wirelessly. The approach is informed by peer-reviewed research on contact-based acoustic respiratory monitoring, which reports clinically relevant accuracy under motion and environmental noise. Validation is ongoing for robustness across diverse users and conditions.

Applications span consumer and clinical domains: stress and focus management, athletic recovery and training, sleep quality, and breathing rehabilitation for people with respiratory or anxiety conditions. The same continuous-respiration platform extends naturally toward remote patient monitoring and early detection of respiratory deterioration, settings where continuous, unobtrusive measurement has remained technically out of reach.

The market is validated and immediate. Alveos One has a waiting list of more than 7,000 people, pre-orders are live, and first units ship in Q4 2026 at a $399 retail price with no required subscription. The company is backed by early-stage investor Antler and combines expertise in machine learning, hardware, and design.

Breathing has been hidden in plain sight as a vital sign for decades. Alveos One finally measures it continuously, noninvasively, and in real time - and uses it to help people shift their state, protect their health, and understand themselves better.